Stoke Therapeutics Inc - Asset Resilience Ratio
Stoke Therapeutics Inc (STOK) has an Asset Resilience Ratio of 42.39% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Stoke Therapeutics Inc total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Stoke Therapeutics Inc's Asset Resilience Ratio has changed over time. See Stoke Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Stoke Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Stoke Therapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $187.89 Million | 42.39% |
| Total Liquid Assets | $187.89 Million | 42.39% |
Asset Resilience Insights
- Very High Liquidity: Stoke Therapeutics Inc maintains exceptional liquid asset reserves at 42.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Stoke Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Stoke Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Stoke Therapeutics Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Stoke Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 47.90% | $200.45 Million | $418.43 Million | +15.16pp |
| 2024-12-31 | 32.74% | $88.92 Million | $271.56 Million | +28.38pp |
| 2023-12-31 | 4.36% | $9.95 Million | $228.34 Million | -40.96pp |
| 2022-12-31 | 45.32% | $116.04 Million | $256.07 Million | +13.95pp |
| 2021-12-31 | 31.36% | $74.92 Million | $238.87 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $297.93 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $107.54 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $2.44 Million | -- |
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials fo… Read more